SIX1 protein expression selectively identifies blastemal elements in Wilms tumor

Pediatric Blood and Cancer

Volumn 59, Issue 1, 2012, Pages 62-68

  Sehic, Daniel ^a   Karlsson, Jenny ^a   Sandstedt, Bengt ^b   Gisselsson, David ^a  

^a LUND UNIVERSITY   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Blastema; Meta analysis; Microarray; SIX1; SIX2; Wilms tumor

Indexed keywords

ANTINEOPLASTIC AGENT; PARAFFIN; TRANSCRIPTION FACTOR SIX1;

ARTICLE; BIOINFORMATICS; BLASTEMA; CANCER CHEMOTHERAPY; CANCER PATIENT; CHILD; CLINICAL ASSESSMENT; CONTROLLED STUDY; EMBEDDING; FEMALE; FETUS; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE OVEREXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOFLUORESCENCE TEST; INFANT; KIDNEY; KIDNEY DEVELOPMENT; MAJOR CLINICAL STUDY; MALE; NEPHROBLASTOMA; NEPHROGENESIS; NUCLEOTIDE SEQUENCE; PATHOPHYSIOLOGY; PEDIATRICS; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN MICROARRAY; SCHOOL CHILD; TISSUE SECTION; TUMOR CELL LINE;

AGED; CHILD; CHILD, PRESCHOOL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HOMEODOMAIN PROTEINS; HUMANS; INFANT; KIDNEY NEOPLASMS; MALE; NEOPLASM PROTEINS; TUMOR MARKERS, BIOLOGICAL; WILMS TUMOR;

EID: 84861203782     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.24025     Document Type: Article

References (28)

1. Davidoff AM. Wilms' tumor. Curr Opin Pediatr 2009; 21: 357-364.
2. Pritchard-Jones K. Controversies and advances in the management of Wilms' tumour. Arch Dis Child 2002; 87: 241-244.
3. Rivera MN, Haber DA. Wilms' tumour: Connecting tumorigenesis and organ development in the kidney. Nat Rev Cancer 2005; 5: 699-712.
4. Fukuzawa R, Reeve AE. Molecular pathology and epidemiology of nephrogenic rests and Wilms tumors. J Pediatr Hematol Oncol 2007; 29: 589-594.
5. Vujanic GM, Sandstedt B. The pathology of Wilms' tumour (nephroblastoma): The International Society of Paediatric Oncology approach. J Clin Pathol 2010; 63: 102-109.
6. Li CM, Guo M, Borczuk A, et al. Gene expression in Wilms' tumor mimics the earliest committed stage in the metanephric mesenchymal-epithelial transition. Am J Pathol 2002; 160: 2181-2190.
7. Aiden AP, Rivera MN, Rheinbay E, et al. Wilms tumor chromatin profiles highlight stem cell properties and a renal developmental network. Cell Stem Cell 2010; 6: 591-602.
8. Yusenko MV, Kuiper RP, Boethe T, et al. High-resolution DNA copy number and gene expression analyses distinguish chromophobe renal cell carcinomas and renal oncocytomas. BMC Cancer 2009; 9: 152.
9. Cutcliffe C, Kersey D, Huang CC, et al. Clear cell sarcoma of the kidney: Up-regulation of neural markers with activation of the sonic hedgehog and Akt pathways. Clin Cancer Res 2005; 11: 7986-7994.
10. Corbin M, de Reynies A, Rickman DS, et al. WNT/beta-catenin pathway activation in Wilms tumors: A unifying mechanism with multiple entries? Genes Chromosomes Cancer 2009; 48: 816-827.
11. Mengelbier LH, Karlsson J, Lindgren D, et al. Deletions of 16q in Wilms tumors localize to blastemal-anaplastic cells and are associated with reduced expression of the IRXB renal tubulogenesis gene cluster. Am J Pathol 2010; 177: 2609-2621.
12. Yajima H, Motohashi N, Ono Y, et al. Six family genes control the proliferation and differentiation of muscle satellite cells. Exp Cell Res 2010; 316: 2932-2944.
13. Neilson KM, Pignoni F, Yan B, et al. Developmental expression patterns of candidate cofactors for vertebrate six family transcription factors. Dev Dyn 2010; 239: 3446-3466.
14. Konishi Y, Ikeda K, Iwakura Y, et al. Six1 and Six4 promote survival of sensory neurons during early trigeminal gangliogenesis. Brain Res 2006; 1116: 93-102.
15. Zou D, Silvius D, Fritzsch B, et al. Eya1 and Six1 are essential for early steps of sensory neurogenesis in mammalian cranial placodes. Development 2004; 131: 5561-5572.
16. Laclef C, Souil E, Demignon J, et al. Thymus, kidney and craniofacial abnormalities in Six 1 deficient mice. Mech Dev 2003; 120: 669-679.
17. Ozaki H, Nakamura K, Funahashi J, et al. Six1 controls patterning of the mouse otic vesicle. Development 2004; 131: 551-562.
18. Ruf RG, Xu PX, Silvius D, et al. SIX1 mutations cause branchio-oto-renal syndrome by disruption of EYA1-SIX1-DNA complexes. Proc Natl Acad Sci USA 2004; 101: 8090-8095.
19. Xu PX, Zheng W, Huang L, et al. Six1 is required for the early organogenesis of mammalian kidney. Development 2003; 130: 3085-3094.
20. Christensen KL, Patrick AN, McCoy EL, et al. The six family of homeobox genes in development and cancer. Adv Cancer Res 2008; 101: 93-126.
21. Reichenberger KJ, Coletta RD, Schulte AP, et al. Gene amplification is a mechanism of Six1 overexpression in breast cancer. Cancer Res 2005; 65: 2668-2675.
22. Micalizzi DS, Christensen KL, Jedlicka P, et al. The Six1 homeoprotein induces human mammary carcinoma cells to undergo epithelial-mesenchymal transition and metastasis in mice through increasing TGF-beta signaling. J Clin Invest 2009; 119: 2678-2690.
23. Behbakht K, Qamar L, Aldridge CS, et al. Six1 overexpression in ovarian carcinoma causes resistance to TRAIL-mediated apoptosis and is associated with poor survival. Cancer Res 2007; 67: 3036-3042.
24. Yu Y, Khan J, Khanna C, et al. Expression profiling identifies the cytoskeletal organizer ezrin and the developmental homeoprotein Six-1 as key metastatic regulators. Nat Med 2004; 10: 175-181.
25. Ng KT, Man K, Sun CK, et al. Clinicopathological significance of homeoprotein Six1 in hepatocellular carcinoma. Br J Cancer 2006; 95: 1050-1055.
26. Radisky DC. Defining a role for the homeoprotein Six1 in EMT and mammary tumorigenesis. J Clin Invest 2009; 119: 2528-2531.
27. McCoy EL, Iwanaga R, Jedlicka P, et al. Six1 expands the mouse mammary epithelial stem/progenitor cell pool and induces mammary tumors that undergo epithelial-mesenchymal transition. J Clin Invest 2009; 119: 2663-2677.
28. Micalizzi DS, Wang CA, Farabaugh SM, et al. Homeoprotein Six1 increases TGF-beta type I receptor and converts TGF-beta signaling from suppressive to supportive for tumor growth. Cancer Res 2010; 70: 10371-10380.